Cognitive Behavioral Therapy-Based Comprehensive Self-Management Program Improves Presenteeism in Persons with Irritable Bowel Syndrome: A Secondary Data Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Study Protocol
2.3. Intervention
2.4. Measures
2.4.1. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (WPAI-IBS) Questionnaire
2.4.2. Daily Diary Measures
2.4.3. Participant Demographic Characteristics
2.5. Statistical Analysis
3. Results
3.1. Baseline Demographics, Work Productivity and Activity-Impairment Status
3.2. Effect of CSM on Absenteeism, Presenteeism, Overall Work Productivity and Activity Impairment
3.3. Relationship between Daily Diary and WPAI-IBS Measures
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Drossman, D.A.; Hasler, W.L. Rome IV—Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology 2016, 150, 1257–1261. [Google Scholar] [CrossRef] [PubMed]
- Quigley, E.M.; Fried, M.; Gwee, K.-A.; Khalif, I.; Hungin, A.P.; Lindberg, G.; Abbas, Z.; Fernandez, L.B.; Bhatia, S.J.; Schmulson, M.; et al. World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015. J. Clin. Gastroenterol. 2016, 50, 704–713. [Google Scholar] [CrossRef] [Green Version]
- Canavan, C.; West, J.; Card, T. Review Article: The Economic Impact of the Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 2014, 40, 1023–1034. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lacy, B.E.; Mearin, F.; Chang, L.; Chey, W.D.; Lembo, A.J.; Simren, M.; Spiller, R. Bowel disorders. Gastroenterology 2016, 150, 1393–1407.e5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Han, C.J.; Pike, K.; Jarrett, M.E.; Heitkemper, M.M. Symptom-Based Latent Classes of Persons with Irritable Bowel Syndrome. Res. Nurs. Health 2019, 42, 382–391. [Google Scholar] [CrossRef] [PubMed]
- Grover, M.; Kolla, B.P.; Pamarthy, R.; Mansukhani, M.P.; Breen-Lyles, M.; He, J.-P.; Merikangas, K.R. Psychological, Physical, and Sleep Comorbidities and Functional Impairment in Irritable Bowel Syndrome: Results from A National Survey of U.S. Adults. PLoS ONE 2021, 16, e0245323. [Google Scholar] [CrossRef] [PubMed]
- Ballou, S.; Keefer, L. The Impact of Irritable Bowel Syndrome on Daily Functioning: Characterizing and Understanding Daily Consequences of IBS. Neurogastroenterol. Motil. 2017, 29, e12982. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Frändemark, Å.; Törnblom, H.; Jakobsson, S.; Simrén, M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted problem. Am. J. Gastroenterol. 2018, 113, 1540–1549. [Google Scholar] [CrossRef]
- Lackner, J.M.; Jaccard, J.; Krasner, S.S.; Katz, L.A.; Gudleski, G.D.; Blanchard, E.B. How Does Cognitive Behavior Therapy for Irritable Bowel Syndrome Work? A Mediational Analysis of A Randomized Clinical Trial. Gastroenterology 2007, 133, 433–444. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ford, A.C.; Lacy, B.E.; Harris, L.A.; Quigley, E.M.M.; Moayyedi, P. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Snalysis. Am. J. Gastroenterol. 2019, 114, 21–39. [Google Scholar] [CrossRef] [PubMed]
- Jarrett, M.E.; Cain, K.C.; Burr, R.L.; Hertig, V.L.; Rosen, S.N.; Heitkemper, M.M. Comprehensive self-management for irritable bowel syndrome: Randomized trial of in-person vs. combined in-person and telephone sessions. Am. J. Gastroenterol. 2009, 104, 3004–3014. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kjørstad, K.; Sivertsen, B.; Vedaa, Ø.; Langsrud, K.; Faaland, P.M.; Vethe, D.; Vestergaard, C.L.; Scott, J.; Kallestad, H. The Effect of Reducing Insomnia Severity on Work- and Activity-Related Impairment. Behav. Sleep Med. 2020, 19, 505–515. [Google Scholar] [CrossRef] [PubMed]
- Shaffer, K.M.; Finkelstein, E.A.; Camacho, F.; Ingersoll, K.S.; Thorndike, F.; Ritterband, L.M. Effects of An Internet-Based Cognitive Behavioral Therapy for Insomnia Program on Work Productivity: A Secondary Analysis. Ann. Behav. Med. 2020, 55, 592–599. [Google Scholar] [CrossRef] [PubMed]
- Ezawa, I.D.; Bartels, G.C.; Strunk, D.R. Getting Down to Business: An Examination of Occupational outcomes in Cognitive Behavioral Therapy for Depression. Cog. Behav. Ther. 2021, 50, 479–491. [Google Scholar] [CrossRef] [PubMed]
- McCrone, P.; Knapp, M.; Kennedy, T.; Seed, P.T.; Jones, R.; Darnley, S.; Chalder, T. Cost-Effectiveness of Cognitive Behaviour Therapy in Addition to Mebeverine for Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 2008, 20, 255–263. [Google Scholar] [CrossRef] [PubMed]
- Creed, F.; Fernandes, L.; Guthrie, E.; Palmer, S.; Ratcliffe, J.; Read, N.; Rigby, C.; Thompson, D.; Tomenson, B. The Cost-Effectiveness of Psychotherapy and Paroxetine for Severe Irritable Bowel Syndrome. Gastroenterology 2003, 124, 303–317. [Google Scholar] [CrossRef] [PubMed]
- Andersson, E.; Ljótsson, B.; Smit, F.; Paxling, B.; Hedman, E.; Lindefors, N.; Andersson, G.; Rück, C. Cost-Effectiveness of Internet-Based Cognitive Behavior Therapy for Irritable Bowel Syndrome: Results from a Randomized Controlled Trial. BMC Public Health 2011, 11, 215. [Google Scholar] [CrossRef] [Green Version]
- Kamp, K.J.; Weaver, K.R.; Sherwin, L.B.; Barney, P.; Hwang, S.-K.; Yang, P.-L.; Burr, R.L.; Cain, K.C.; Heitkemper, M.M. Effects of a Comprehensive Self-Management Intervention on Extraintestinal Symptoms among Patients with IBS. J. Psychosom. Res. 2019, 126, 109821. [Google Scholar] [CrossRef]
- Mattke, S.; Balakrishnan, A.; Bergamo, G.; Newberry, S.J. A Review of Methods to Measure Health-Related Productivity Loss. Am. J. Manag. Care 2007, 13, 211–217. [Google Scholar]
- Buono, J.L.; Tourkodimitris, S.; Sarocco, P.; Johnston, J.M.; Carson, R.T. Impact of Linaclotide Treatment on Work Productivity and Activity Impairment in Adults with Irritable Bowel Syndrome with Constipation: Results from 2 Randomized, Double-Blind, Placebo-Controlled Phase 3 Trials. Am. Health Drug. Benefits 2014, 7, 289–297. [Google Scholar] [PubMed]
- Jones, M.; Walter, S.; Faresjö, Å.; Grodzinsky, E.; Kjellström, L.; Viktorsson, L.; Talley, N.J.; Agreus, L.; Andreasson, A. Gastrointestinal Recall Questionnaires Compare Poorly with Prospective Patient Diaries for Gastrointestinal Symptoms: Data from Population and Primary Health Centre Samples. Eur. J. Gastroenterol. Hepatol. 2019, 31, 163–169. [Google Scholar] [CrossRef]
- Bolger, N.; Davis, A.; Rafaeli, E. Diary Methods: Capturing Life as It is Lived. Ann. Rev. Psychol. 2003, 54, 579–616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pocock, S.J. Clinical Trials: A Practical Approach; John Wiley & Sons: Chichester, UK, 2013. [Google Scholar]
- Barney, P.; Weisman, P.; Jarrett, M.; Levy, R.; Heitkemper, M. Master Your IBS: An 8 Week Plan Proven to Control the Symptoms of Irritable Bowel Syndrome; AGA Institute Press: Bethesda, MD, USA, 2010. [Google Scholar]
- Reilly, M.C.; Bracco, A.; Ricci, J.-F.; Santoro, J.; Stevens, T. The Validity and Accuracy of the Work Productivity and Activity Impairment Questionnaire –Irritable Bowel Syndrome Version (WPAI:IBS). Aliment. Pharmacol. Ther. 2004, 20, 459–467. [Google Scholar] [CrossRef] [PubMed]
- Stawski, R.S.; Bosker, R.J. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling; SAGE Publications: Los Angeles, CA, USA, 2013. [Google Scholar]
- Nunes, E.V.; Pavlicova, M.; Hu, M.-C.; Campbell, A.N.; Miele, G.; Hien, D.; Klein, D.F. Baseline Matters: The Importance of Covariation for Baseline Severity in the Analysis of Clinical Trials. Am. J. Drug. Alcohol. Abuse 2011, 37, 446–452. [Google Scholar] [CrossRef] [Green Version]
- Reilly, M.C.; Barghout, V.; McBurney, C.R.; Niecko, T.E. Effect of Tegaserod on Work and Daily Activity in Irritable Bowel Syndrome with Constipation. Aliment. Pharmacol. Ther. 2005, 22, 373–380. [Google Scholar] [CrossRef] [PubMed]
- Tack, J.; Müller-Lissner, S.; Bytzer, P.; Corinaldesi, R.; Chang, L.; Viegas, A.; Schnekenbuehl, S.; Dunger-Baldauf, C.; Rueegg, P. A Randomised Controlled Trial Assessing the Efficacy and Safety of Repeated Tegaserod Therapy in Women with Irritable Bowel Syndrome with Constipation. Gut 2005, 54, 1707–1713. [Google Scholar] [CrossRef]
- Eswaran, S.; Chey, W.D.; Jackson, K.; Pillai, S.; Chey, S.W.; Han-Markey, T. A Diet Low in Fermentable Oligo-, Di-, and Monosaccharides and Polyols improves quality of life and reduces activity impairment in patients with irritable bowel syndrome and diarrhea. Clin. Gastroenterol. Hepatol. 2017, 15, 1890–1899.e3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Laird, K.T.; Tanner-Smith, E.E.; Russell, A.C.; Hollon, S.D.; Walker, L.S. Short-Term and Long-Term Efficacy of Psychological Therapies for Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. Clin. Gastroenterol. Hepatol. 2016, 14, 937–947.e4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zia, J.K.; Barney, P.; Cain, K.C.; Jarrett, M.E.; Heitkemper, M.M. A Comprehensive Self-Management Irritable Bowel Syndrome Program Produces Sustainable Changes in Behavior after 1 Year. Clin. Gastroenterol. Hepatol. 2016, 14, e1–e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dean, B.B.; Aguilar, D.; Barghout, V.; Kahler, K.H.; Frech, F.; Groves, D.; Ofman, J.J. Impairment in Work Productivity and Health-Related Quality of Life in Patients with IBS. Am. J. Manag. Care 2005, 11, S17–S26. [Google Scholar] [PubMed]
- Self, M.M.; Williams, A.E.; Czyzewski, D.I.; Weidler, E.M.; Shulman, R.J. Agreement between Prospective Diary Data and Retrospective Questionnaire Report of Abdominal Pain and Stooling Symptoms in Children with Irritable Bowel Syndrome. Neurogastroenterol. Motil. 2015, 27, 1110–1119. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sullivan, G.M.; Feinn, R. Using Effect Size-or Why the P Value Is Not Enough. J. Grad. Med. Educ. 2012, 4, 279–282. [Google Scholar] [CrossRef] [Green Version]
Measure | Sample n = 160 | |||||
CSM n = 107 | UC n = 53 | |||||
N 1 | n | % | N 1 | n | % | |
Gender, females | 107 | 94 | 88% | 53 | 46 | 87% |
Race, white | 106 | 88 | 83% | 53 | 48 | 91% |
Education, college | 107 | 75 | 70% | 53 | 29 | 55% |
Employed/Student | 100 | 81 | 81% | 48 | 37 | 77.1% |
Age (mean, SD) | 107 | 45.07 | (14.09) | 53 | 44.11 | (13.95) |
M | (SD) | M | (SD) | |||
WPAI-IBS 3 | ||||||
Absenteeism 2 (%) | 71 | 2.59 | (6.30) | 40 | 1.90 | (4.89) |
Presenteeism 2 (%) | 71 | 26.53 | (21.24) | 40 | 22.50 | (20.22) |
Overall work productivity loss 2 (%) | 71 | 28.00 | (21.69) | 40 | 23.19 | (20.93) |
Activity impairment (%) | 106 | 30.57 | (21.42) | 52 | 33.46 | (22.74) |
Daily Diary 4 | ||||||
Absenteeism 2 (%) | 81 | 0.53 | (2.67) | 44 | 0.96 | (2.97) |
Presenteeism 2 | 85 | 1.56 | (0.45) | 46 | 1.58 | (0.53) |
Overall productivity loss | 107 | 1.65 | (0.45) | 53 | 1.72 | (0.48) |
IBS interference | 107 | 1.59 | (0.44) | 53 | 1.65 | (0.48) |
Measure | Sample n = 160 | ||||||||
---|---|---|---|---|---|---|---|---|---|
CSM | UC | Group Fixed Effects | |||||||
M | (SD) | M | (SD) | Coefficient (95% CI) | p1 | Effsize | p2 | ||
WPAI-IBS | |||||||||
Absenteeism (%) | Main 3 | −2.98 (−5.44, −0.51) | 0.02 | −0.19 | 0.02 | ||||
Inter 4 | −3.27 (−6.50, −0.05) | 0.05 | −0.16 | ||||||
3 Months | −2.34 | (6.28) | 4.97 | (19.69) | |||||
6 Months | −2.16 | (5.86) | 0.21 | (4.90) | |||||
12 Months | −1.11 | (7.42) | 0.16 | (4.64) | |||||
Presenteeism (%) | Main 3 | −10.58 (−16.14, −5.05) | <0.01 | −0.30 | <0.01 | ||||
Inter 4 | −7.71 (−13.53, −1.85) | 0.01 | −0.21 | ||||||
3 Months | −10.63 | (23.34) | 3.87 | (16.06) | |||||
6 Months | −12.26 | (22.28) | −0.56 | (20.13) | |||||
12 Months | −12.81 | (25.10) | 1.43 | (21.98) | |||||
Overall work productivity loss (%) | Main 3 | −10.04 (−15.90, −4.21) | <0.01 | −0.27 | <0.01 | ||||
Inter 4 | −9.09 (−12.16, −2.97) | <0.01 | −0.23 | ||||||
3 Months | −12.21 | (24.32) | 4.94 | (19.66) | |||||
6 Months | −12.13 | (23.48) | −1.15 | (19.93) | |||||
12 Months | −13.42 | (26.13) | −1.14 | (21.17) | |||||
Activity impairment (%) | Main 3 | −12.33 (−17.22, −7.47) | <0.01 | −0.31 | <0.01 | ||||
Inter 4 | −8.38 (−13.18, −3.56) | <0.01 | −0.27 | ||||||
3 Months | −14.62 | (24.49) | −1.43 | (23.54) | |||||
6 Months | −13.07 | (23.01) | −5.49 | (18.15) | |||||
12 Months | −14.59 | (26.29) | −5.88 | (26.99) | |||||
Diary items | |||||||||
Absenteeism (%) | The model failed to converge | ||||||||
3 Months | −0.58 | (2.83) | −1.08 | (3.26) | |||||
6 Months | 0.59 | (4.97) | −0.41 | (2.48) | |||||
12 Months | 1.15 | (5.28) | 0.27 | (4.36) | |||||
Presenteeism | Main 3 | −0.16 (−0.22, −0.05) | <0.01 | −0.22 | <0.01 | ||||
Inter 4 | −0.09 (−0.20, 0.02) | 0.12 | −0.12 | ||||||
3 Months | −0.18 | (0.40) | −0.02 | (0.42) | |||||
6 Months | −0.16 | (0.38) | 0.01 | (0.41) | |||||
12 Months | −0.18 | (0.38) | −0.02 | (0.37) | |||||
Overall productivity loss | Main 3 | −0.20 (−0.29, −0.10) | <0.01 | −0.32 | <0.01 | ||||
Inter 4 | −0.11 (−0.20, −0.01) | 0.03 | −0.18 | ||||||
3 Months | −0.22 | (0.40) | −0.02 | (0.38) | |||||
6 Months | −0.22 | (0.37) | −0.04 | (0.35) | |||||
12 Months | −0.22 | (0.40) | −0.08 | (0.30) | |||||
IBS interference | Main 3 | −0.19 (−0.28, −0.09) | <0.01 | −0.31 | <0.01 | ||||
Inter 4 | −0.11 (−0.20, −0.15) | 0.02 | −0.18 | ||||||
3 Months | −0.21 | (0.40) | −0.05 | (0.36) | |||||
6 Months | −0.21 | (0.36) | −0.04 | (0.34) | |||||
12 Months | −0.22 | (0.40) | −0.09 | (0.30) |
Measure | Correlations | ||
---|---|---|---|
Daily Diary | WPAI-IBS | r1 (95% CI) | p |
Absenteeism | Absenteeism | 0.03 (−0.13, 0.18) | 0.75 |
Presenteeism | Presenteeism | 0.51 (0.39, 0.62) | <0.01 |
Overall productivity loss | Overall work productivity loss | 0.45 (0.32, 0.57) | <0.01 |
IBS interference | Activity impairment | 0.44 (0.31, 0.56) | <0.01 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yang, P.-L.; Matthews, S.W.; Burr, R.L.; Cain, K.C.; Barney, P.G.; Zia, J.K.; Heitkemper, M.H.; Kamp, K.J. Cognitive Behavioral Therapy-Based Comprehensive Self-Management Program Improves Presenteeism in Persons with Irritable Bowel Syndrome: A Secondary Data Analysis. Int. J. Environ. Res. Public Health 2022, 19, 3003. https://doi.org/10.3390/ijerph19053003
Yang P-L, Matthews SW, Burr RL, Cain KC, Barney PG, Zia JK, Heitkemper MH, Kamp KJ. Cognitive Behavioral Therapy-Based Comprehensive Self-Management Program Improves Presenteeism in Persons with Irritable Bowel Syndrome: A Secondary Data Analysis. International Journal of Environmental Research and Public Health. 2022; 19(5):3003. https://doi.org/10.3390/ijerph19053003
Chicago/Turabian StyleYang, Pei-Lin, Sarah W. Matthews, Robert L. Burr, Kevin C. Cain, Pamela G. Barney, Jasmine K. Zia, Margaret H. Heitkemper, and Kendra J. Kamp. 2022. "Cognitive Behavioral Therapy-Based Comprehensive Self-Management Program Improves Presenteeism in Persons with Irritable Bowel Syndrome: A Secondary Data Analysis" International Journal of Environmental Research and Public Health 19, no. 5: 3003. https://doi.org/10.3390/ijerph19053003
APA StyleYang, P. -L., Matthews, S. W., Burr, R. L., Cain, K. C., Barney, P. G., Zia, J. K., Heitkemper, M. H., & Kamp, K. J. (2022). Cognitive Behavioral Therapy-Based Comprehensive Self-Management Program Improves Presenteeism in Persons with Irritable Bowel Syndrome: A Secondary Data Analysis. International Journal of Environmental Research and Public Health, 19(5), 3003. https://doi.org/10.3390/ijerph19053003